The phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma.
The case is reported of a patient with pulmonary metastases from a renal adenocarcinoma who experienced subjective improvement and objective tumor regression on Bacillus Calmette-Guerin (BCG) and megestrol acetate therapy. In a subsequent Phase II trial, no objective responses were noted among 15 patients treated with megestrol acetate (160 mg/day X 56 days) and BCG (five immunizing doses intradermally, every 2 weeks X 5). It is concluded that this treatment regimen is not clinically useful in patients with metastatic renal adenocarcinoma.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007271:Injections, Intradermal; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male; D008535:Megestrol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012882:Skin Tests
D001500:BCG Vaccine; D007136:Immunoglobulins; D008535:Megestrol